GleamWall
中文EN

RNTX Rein Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1420565 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY15.6%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-100.5%
ROA-87.9%
ROIC (approx.)-85.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets11.2%
Debt / equity0.00x
Current ratio6.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.45x
Accruals ratio-48.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$4.38M$3.64M$3.07M$2.00M$1.68M$4.29M$3.05M$3.32M
SG&A expense$2.62M$2.44M$2.16M$1.96M$3.81M$2.58M$2.56M$2.48M
Operating income-$7.00M-$6.08M-$5.23M-$32.66M-$5.49M-$6.87M-$5.61M-$42.80M
Net income-$5.54M-$6.38M-$5.84M-$31.97M-$5.58M-$6.82M-$5.50M-$40.98M
EBITDA-$7.00M——-$32.66M-$5.49M-$6.87M-$5.61M-$42.80M
EPS (basic)-0.06-0.10-0.19—-0.21-0.28-0.25—
EPS (diluted)-0.06-0.10-0.19—-0.21-0.28-0.25—
Dividends declared per share0.000.000.000.000.000.000.000.00
Weighted avg. shares (diluted)88.33M67.08M30.35M—26.36M24.19M21.92M—
Balance sheet
Cash & equivalents$943,000$8.54M$4.45M$3.21M$4.05M$5.72M$7.43M$12.87M
Short-term investments$34.55M$32.10M—$0————
Current assets$36.78M$41.45M$5.45M$4.33M$5.17M$6.60M$8.33M$13.66M
PP&E, net———$0$0$1,000$1,000$1,000
Goodwill$6.33M$6.33M$6.33M$6.33M$6.33M$6.33M$6.33M$6.33M
Intangibles$13.50M$13.50M$13.50M$13.50M$42.20M$42.20M$42.20M$42.20M
Total assets$59.43M$65.97M$26.29M$24.16M$53.71M$57.48M$57.63M$62.19M
Current liabilities$5.60M$9.71M$13.64M$6.18M$5.74M$7.69M$5.98M$5.75M
Total liabilities$6.66M$10.77M$14.70M$7.24M$7.52M$9.47M$7.75M$7.80M
Shareholders' equity$52.77M$55.20M$11.59M$16.92M$46.19M$48.01M$49.88M$54.39M
Shares outstanding86.27M85.77M28.04M27.55M25.14M23.05M22.01M21.67M
Cash flow statement
Operating cash flow-$7.27M-$8.64M-$3.42M-$3.22M-$3.55M-$6.42M-$6.17M-$4.81M
Investing cash flow-$329,000———$0——$0
Financing cash flow$0$47.81M$4.65M$2.40M$1.90M$4.71M$738,000$1,000
Depreciation & amortization$0——$0$0$1,000$0$0
Stock-based compensation$534,000$164,000$156,000$257,000$1.45M$256,000$264,000$133,000

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.